Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 35,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Hematological Malignancies
Interventions: Naive T Cell Depleted Donor Lymphocyte Infusion; Biological
Lead sponsor: Mitchell Horwitz, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Severe Combined Immunodeficiency
Interventions: Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 3 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus (HIV), Sexually Transmitted Disease (STD)
Interventions: STAND HIV Risk Reduction Intervention, Text Messaging Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 391 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Transplant
Interventions: Exercise Rehabilitation; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rhytides
Interventions: PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA; Drug
Lead sponsor: Lupo Center for Aesthetic and General Dermatology; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Socket Preservation
Interventions: MinerOss® X Plug, Striate+ Membrane; Device
Lead sponsor: Harvard School of Dental Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: FL115; Drug
Lead sponsor: Suzhou Forlong Biotechnology Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Newport Beach, California • San Diego, California • Canton, Ohio

Conditions: Asthma
Interventions: RNS60, Normal Saline, Budesonide; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Costa Mesa, California • Los Angeles, California • Riverside, California

Conditions: Psychedelic Experiences, Amnesia
Interventions: Psilocybin and Midazolam; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Partially Edentulous Maxilla or Mandible
Interventions: PrimeTaper EV; Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 25 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Aurora, Colorado • Broomfield, Colorado • Oakbrook Terrace, Illinois + 5 more

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®), anastrazole (Arimidex®); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more

Conditions: Healthy Volunteers
Interventions: SHP643; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: GP2 peptide + GM-CSF vaccine, GM-CSF (sargramostim), AE37 + GM-CSF vaccine; Biological
Lead sponsor: San Antonio Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 75
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more

Conditions: Atrial Arrhythmia
Interventions: Acorys Mapping System; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COVID-19
Interventions: Motivational Interviewing, COVID-19 Symptom Monitoring System, Motivational Interviewing and COVID-19 Symptom Monitoring System, Supportive Services; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Hodgkin Lymphoma
Interventions: Mocetinostat Plus Brentuximab Vedotin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Nab-paclitaxel, IG-001; Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Chattanooga, Tennessee • Memphis, Tennessee + 1 more

Conditions: Asthma
Interventions: Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 56
States / cities: Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more

Conditions: MISC Intervention, Treatment as Usual
Interventions: MISC intervention, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 7 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide; Other · Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Enteral Nutrition
Interventions: TubeClear® intervention; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions: Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more

Conditions: Healthy
Interventions: LY3410738, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Search by objective public record fields.

Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Socket Preservation With BioHorizon's Striate+ Membrane and MinerOss X Plug

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

Pilot RECAP Study in Healthy Volunteers

Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Vaccine Therapy in Treating Patients With Breast Cancer

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

ACORYS AI4AF PILOT STUDY

Protecting Native Families From COVID-19

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

MISC-IPV: A Community-Based Intervention for Children Traumatized by Intimate Partner Violence

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

TubeClear® Evaluation in Pediatric Patients (Phase I)

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A Study of LY3410738 in Healthy Adult Participants